Shopping Cart 0
Cart Subtotal
AED 0

Pfenex Inc (PFNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company's lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple sclerosis; PF708, a peptide product candidate to treat high-risk fracture patients; and others. Pfenex's preclinical products under development include PF529, a biosimilar candidate to neulasta; PF688, a biosimilar candidate to cimzia, PF444, PF690; and others. The company produces biosimilar product with protein production platform and bioanalytic approach. It partners with the US government for developing vaccines for anthrax and malaria. Pfenex is headquartered in San Diego, California, the US.

Pfenex Inc (PFNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pfenex Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Pfenex Enters into Research Agreement with Path Vaccine Solutions 11

Pfenex Forms Joint Venture With Agila Biotech 12

Pfenex Enters Into Co-Development Agreement With DNA2.0 13

Pfenex Enters Into Co-Development Agreement With ProZyme 14

Licensing Agreements 15

Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15

Pfenex Enters into Licensing Agreement with China NT Pharma Group 16

Jazz Pharma Amends Licensing Agreement with Pfenex 17

Nemucore Medical Enters into Licensing Agreement with Pfenex 19

Equity Offering 20

Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20

Pfenex Raises USD43 Million in Public Offering of Shares 21

Pfenex Raises USD40.4 Million in Public Offering of Shares 23

Pfenex Raises USD50 Million in IPO 25

Pfenex Inc-Key Competitors 26

Pfenex Inc-Key Employees 27

Pfenex Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

May 10, 2018: Pfenex Reports First Quarter 2018 Results and Provides Business Update 29

Mar 15, 2018: Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update 31

Nov 09, 2017: Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update 33

Aug 09, 2017: Pfenex Reports Second Quarter 2017 Results and Provides Business Update 35

May 08, 2017: Pfenex Reports First Quarter 2017 Results and Provides Business Update 37

Mar 15, 2017: Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update 39

Corporate Communications 41

Aug 16, 2018: Pfenex announces departure of chief medical and scientific officer Dr. Hubert Chen 41

Jan 04, 2018: Pfenex Names Susan A. Knudson as CFO 42

Sep 07, 2017: Pfenex Announces Management Changes 43

Aug 03, 2017: Pfenex Names Eef Schimmelpennink Chief Executive Officer 44

Apr 03, 2017: Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors 45

Mar 31, 2017: William R. Rohn Announces Plans To Retire As Chairman And Board Member 46

Jan 24, 2017: Pfenex Announces Leadership Transition 47

Product Approvals 48

May 14, 2018: Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Pfenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pfenex Enters into Research Agreement with Path Vaccine Solutions 11

Pfenex Forms Joint Venture With Agila Biotech 12

Pfenex Enters Into Co-Development Agreement With DNA2.0 13

Pfenex Enters Into Co-Development Agreement With ProZyme 14

Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15

Pfenex Enters into Licensing Agreement with China NT Pharma Group 16

Jazz Pharma Amends Licensing Agreement with Pfenex 17

Nemucore Medical Enters into Licensing Agreement with Pfenex 19

Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20

Pfenex Raises USD43 Million in Public Offering of Shares 21

Pfenex Raises USD40.4 Million in Public Offering of Shares 23

Pfenex Raises USD50 Million in IPO 25

Pfenex Inc, Key Competitors 26

Pfenex Inc, Key Employees 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pfenex Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Pfenex Inc (Pfenex) is a biologics company that develops biosimilar therapeutics. The company's lead product candidate includes, PF582, a biosimilar candidate which is used for the treatment of retinal diseases. It also develops PF530, a biosimilar candidate for the treatment of multiple sclerosis; PF708, a peptide product candidate to treat high-risk fracture patients; and others. Pfenex's preclinical products under development include PF529, a biosimilar candidate to neulasta; PF688, a biosimilar candidate to cimzia, PF444, PF690; and others. The company produces biosimilar product with protein production platform and bioanalytic approach. It partners with the US government for developing vaccines for anthrax and malaria. Pfenex is headquartered in San Diego, California, the US.

Pfenex Inc (PFNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pfenex Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Pfenex Enters into Research Agreement with Path Vaccine Solutions 11

Pfenex Forms Joint Venture With Agila Biotech 12

Pfenex Enters Into Co-Development Agreement With DNA2.0 13

Pfenex Enters Into Co-Development Agreement With ProZyme 14

Licensing Agreements 15

Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15

Pfenex Enters into Licensing Agreement with China NT Pharma Group 16

Jazz Pharma Amends Licensing Agreement with Pfenex 17

Nemucore Medical Enters into Licensing Agreement with Pfenex 19

Equity Offering 20

Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20

Pfenex Raises USD43 Million in Public Offering of Shares 21

Pfenex Raises USD40.4 Million in Public Offering of Shares 23

Pfenex Raises USD50 Million in IPO 25

Pfenex Inc-Key Competitors 26

Pfenex Inc-Key Employees 27

Pfenex Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

May 10, 2018: Pfenex Reports First Quarter 2018 Results and Provides Business Update 29

Mar 15, 2018: Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update 31

Nov 09, 2017: Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update 33

Aug 09, 2017: Pfenex Reports Second Quarter 2017 Results and Provides Business Update 35

May 08, 2017: Pfenex Reports First Quarter 2017 Results and Provides Business Update 37

Mar 15, 2017: Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update 39

Corporate Communications 41

Aug 16, 2018: Pfenex announces departure of chief medical and scientific officer Dr. Hubert Chen 41

Jan 04, 2018: Pfenex Names Susan A. Knudson as CFO 42

Sep 07, 2017: Pfenex Announces Management Changes 43

Aug 03, 2017: Pfenex Names Eef Schimmelpennink Chief Executive Officer 44

Apr 03, 2017: Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors 45

Mar 31, 2017: William R. Rohn Announces Plans To Retire As Chairman And Board Member 46

Jan 24, 2017: Pfenex Announces Leadership Transition 47

Product Approvals 48

May 14, 2018: Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Pfenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pfenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pfenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pfenex Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pfenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pfenex Enters into Research Agreement with Path Vaccine Solutions 11

Pfenex Forms Joint Venture With Agila Biotech 12

Pfenex Enters Into Co-Development Agreement With DNA2.0 13

Pfenex Enters Into Co-Development Agreement With ProZyme 14

Alvogen Malta Operations Enters into Licensing Agreement with Pfenex 15

Pfenex Enters into Licensing Agreement with China NT Pharma Group 16

Jazz Pharma Amends Licensing Agreement with Pfenex 17

Nemucore Medical Enters into Licensing Agreement with Pfenex 19

Pfenex Plans to Raise up to USD120 Million in Public Offering of Securities 20

Pfenex Raises USD43 Million in Public Offering of Shares 21

Pfenex Raises USD40.4 Million in Public Offering of Shares 23

Pfenex Raises USD50 Million in IPO 25

Pfenex Inc, Key Competitors 26

Pfenex Inc, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pfenex Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.